{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T19:23:19Z","timestamp":1788808999555,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10620-025-09647-y","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T19:49:02Z","timestamp":1767642542000},"page":"2365-2373","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Upadacitinib Is Safe and Effective in Older Adults: A Real-World Experience Comparing Safety and Efficacy in Younger Versus\u00a0Older Adults with Inflammatory Bowel Disease"],"prefix":"10.1007","volume":"71","author":[{"given":"Nicole M.","family":"Garcia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Memel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuntao","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Thiemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cooper","family":"Dort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendall","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"9647_CR1","doi-asserted-by":"publisher","first-page":"108402","DOI":"10.1016\/j.pharmthera.2023.108402","volume":"245","author":"OH Nielsen","year":"2023","unstructured":"Nielsen OH, Boye TL, Gubatan J et al. Selective jak1 inhibitors for the treatment of inflammatory bowel disease. Pharmacol Ther 2023;245:108402.","journal-title":"Pharmacol Ther"},{"key":"9647_CR2","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/ibd\/izab052","volume":"27","author":"B Kochar","year":"2021","unstructured":"Kochar B, Kalasapudi L, Ufere NN et al. Systematic review of inclusion and analysis of older adults in randomized controlled trials of medications used to treat inflammatory bowel diseases. Inflamm Bowel Dis 2021;27:1541\u20131543.","journal-title":"Inflamm Bowel Dis"},{"key":"9647_CR3","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1093\/jcag\/gwy051","volume":"2","author":"GC Nguyen","year":"2019","unstructured":"Nguyen GC, Targownik LE, Singh H et al. The impact of inflammatory bowel disease in canada 2018: Ibd in seniors. J Can Assoc Gastroenterol 2019;2:S68-s72.","journal-title":"J Can Assoc Gastroenterol"},{"key":"9647_CR4","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1053\/j.gastro.2019.01.002","volume":"156","author":"S Coward","year":"2019","unstructured":"Coward S, Clement F, Benchimol EI et al. Past and future burden of inflammatory bowel diseases based on modeling of population-based data. Gastroenterology 2019;156:1345\u201353.e4.","journal-title":"Gastroenterology"},{"key":"9647_CR5","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1097\/MIB.0000000000001099","volume":"23","author":"AN Ananthakrishnan","year":"2017","unstructured":"Ananthakrishnan AN, Donaldson T, Lasch K, Yajnik V. Management of inflammatory bowel disease in the elderly patient: Challenges and opportunities. Inflamm Bowel Dis 2017;23:882\u2013893.","journal-title":"Inflamm Bowel Dis"},{"key":"9647_CR6","doi-asserted-by":"crossref","unstructured":"Fries W, Basile G, Bellone F, Costantino G, Viola A. Efficacy and safety of biological therapies and jak inhibitors in older patients with inflammatory bowel disease. Cells 2023;12.","DOI":"10.20944\/preprints202306.0614.v1"},{"key":"9647_CR7","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/ibd\/zaa010.140","volume":"26","author":"N Khan","year":"2020","unstructured":"Khan N, Vallarino C, Lissoos T, Darr U, Luo M. Risk of infection and types of infection among elderly patients with inflammatory bowel disease: A retrospective database analysis. Inflamm Bowel Dis 2020;26:462\u2013468.","journal-title":"Inflamm Bowel Dis"},{"key":"9647_CR8","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1097\/MIB.0000000000000993","volume":"23","author":"GC Nguyen","year":"2017","unstructured":"Nguyen GC, Bernstein CN, Benchimol EI. Risk of surgery and mortality in elderly-onset inflammatory bowel disease: A population-based cohort study. Inflamm Bowel Dis 2017;23:218\u2013223.","journal-title":"Inflamm Bowel Dis"},{"key":"9647_CR9","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/rheumatology\/kead448","volume":"63","author":"PC Taylor","year":"2024","unstructured":"Taylor PC, Choy E, Baraliakos X et al. Differential properties of janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases. Rheumatology (Oxford) 2024;63:298\u2013308.","journal-title":"Rheumatology (Oxford)"},{"key":"9647_CR10","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2017;376:1723\u20131736.","journal-title":"N Engl J Med"},{"key":"9647_CR11","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","volume":"399","author":"S Danese","year":"2022","unstructured":"Danese S, Vermeire S, Zhou W et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: Results from three phase 3, multicentre, double-blind, randomised trials. Lancet 2022;399:2113\u20132128.","journal-title":"Lancet"},{"key":"9647_CR12","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","volume":"388","author":"EV Loftus Jr","year":"2023","unstructured":"Loftus EV Jr, Pan\u00e9s J, Lacerda AP et al. Upadacitinib induction and maintenance therapy for crohn\u2019s disease. N Engl J Med 2023;388:1966\u20131980.","journal-title":"N Engl J Med"},{"key":"9647_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/ibd\/izac084","volume":"29","author":"GR Lichtenstein","year":"2023","unstructured":"Lichtenstein GR, Bressler B, Francisconi C et al. Assessment of safety and efficacy of tofacitinib, stratified by age, in patients from the ulcerative colitis clinical program. Inflamm Bowel Dis 2023;29:27\u201341.","journal-title":"Inflamm Bowel Dis"},{"key":"9647_CR14","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 2022;386:316\u2013326.","journal-title":"N Engl J Med"},{"key":"9647_CR15","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1136\/annrheumdis-2020-eular.2761","volume":"79","author":"K Winthrop","year":"2020","unstructured":"Winthrop K, Calabrese L, Van den Bosch F et al. Fri0141 characterization of serious infections with upadacitinib in patients with rheumatoid arthritis. Ann Rheum Dis 2020;79:654\u2013655.","journal-title":"Ann Rheum Dis"},{"key":"9647_CR16","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1136\/annrheumdis-2020-eular.907","volume":"79","author":"M Weinblatt","year":"2020","unstructured":"Weinblatt M, Mysler E, Ostor A et al. Fri0140 impact of baseline demographics and disease activity on outcomes in patients with rheumatoid arthritis receiving upadacitinib. Ann Rheum Dis 2020;79:653\u2013654.","journal-title":"Ann Rheum Dis"},{"key":"9647_CR17","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.14309\/01.ajg.0000995852.39535.01","volume":"118","author":"N Chowla","year":"2023","unstructured":"Chowla N, Tariq R, Loftus E. S29 safety of upadacitinib in older patients with ulcerative colitis: A real-world experience. Am J Gastroenterol 2023;118:S8\u2013S9.","journal-title":"Am J Gastroenterol"},{"key":"9647_CR18","doi-asserted-by":"publisher","first-page":"1436183","DOI":"10.3389\/fphar.2025.1436183","volume":"16","author":"S Wang","year":"2025","unstructured":"Wang S, Wang X, Ding J et al. Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the fda adverse event reporting system. Front Pharmacol 2025;16:1436183.","journal-title":"Front Pharmacol"},{"key":"9647_CR19","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00535-012-0686-9","volume":"48","author":"M Naganuma","year":"2013","unstructured":"Naganuma M, Kunisaki R, Yoshimura N, Takeuchi Y, Watanabe M. A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel disease. J Gastroenterol 2013;48:595\u2013600.","journal-title":"J Gastroenterol"},{"key":"9647_CR20","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40266-017-0498-y","volume":"34","author":"N Khan","year":"2017","unstructured":"Khan N, Vallarino C, Lissoos T, Darr U, Luo M. Risk of malignancy in a nationwide cohort of elderly inflammatory bowel disease patients. Drugs Aging 2017;34:859\u2013868.","journal-title":"Drugs Aging"},{"key":"9647_CR21","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1093\/ibd\/izy311","volume":"25","author":"J C\u00f4t\u00e9-Daigneault","year":"2019","unstructured":"C\u00f4t\u00e9-Daigneault J, Bessissow T, Nicolae MV et al. Herpes zoster incidence in inflammatory bowel disease patients: A population-based study. Inflamm Bowel Dis 2019;25:914\u2013918.","journal-title":"Inflamm Bowel Dis"},{"key":"9647_CR22","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1093\/ecco-jcc\/jjw054","volume":"10","author":"AN Ananthakrishnan","year":"2016","unstructured":"Ananthakrishnan AN, Shi HY, Tang W et al. Systematic review and meta-analysis: Phenotype and clinical outcomes of older-onset inflammatory bowel disease. J Crohns Colitis 2016;10:1224\u20131236.","journal-title":"J Crohns Colitis"},{"key":"9647_CR23","doi-asserted-by":"crossref","unstructured":"Brassard P, Bitton A, Suissa A, et al. Oral corticosteroids and the risk of serious infections in patients with elderly-onset inflammatory bowel diseases. Am J Gastroenterol 2014;109:1795\u2013802; quiz 803.","DOI":"10.1038\/ajg.2014.313"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09647-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-025-09647-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09647-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T02:26:16Z","timestamp":1783909576000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-025-09647-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["9647"],"URL":"https:\/\/doi.org\/10.1007\/s10620-025-09647-y","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"9 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KB is the principle investigator for clinical trials sponsored by AbbVie, Gilead, and NorthSea therapeutics. NMG, ZM, YZ, AT, CD have no relevant disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}